
In a randomized trial in the DRC (N=597), tecovirimat did not significantly shorten lesion resolution time versus placebo in patients with clade I mpox (7 vs. 8 days; HR=1.13, P=0.14). Safety profiles were comparable (72.9% vs. 70.5% with adverse events). No virologic advantage was noted at day 14. Findings suggest limited clinical benefit for tecovirimat in clade I mpox despite reassuring safety.
Like
Save
Share